Abbott Laboratories Past Earnings Performance
Past criteria checks 2/6
Abbott Laboratories has been growing earnings at an average annual rate of 14.5%, while the Medical Equipment industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 7.2% per year. Abbott Laboratories's return on equity is 14.5%, and it has net margins of 13.9%.
Key information
14.5%
Earnings growth rate
14.9%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 7.2% |
Return on equity | 14.5% |
Net Margin | 13.9% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up
Oct 24Abbott: A Diversified Health Care Company With Strong Underlying Growth
Oct 20Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
Sep 29Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price
Sep 26Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
Sep 17We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Abbott: This Dividend King Is Ready For Takeoff
Jul 31Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement
Jul 17The Big Trends: New Frontiers in Healthcare
Jul 13Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital
Jul 12Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Jun 25Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)
Jun 23Revenue & Expenses BreakdownBeta
How Abbott Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 40,326 | 5,608 | 10,597 | 2,651 |
31 Dec 23 | 40,109 | 5,701 | 10,385 | 2,619 |
30 Sep 23 | 39,959 | 5,142 | 10,542 | 2,603 |
30 Jun 23 | 40,226 | 5,140 | 10,598 | 2,724 |
31 Mar 23 | 41,505 | 5,779 | 10,630 | 2,693 |
31 Dec 22 | 43,653 | 6,905 | 10,703 | 2,741 |
30 Sep 22 | 45,030 | 7,857 | 10,901 | 2,921 |
30 Jun 22 | 45,548 | 8,520 | 10,971 | 2,811 |
31 Mar 22 | 44,514 | 7,695 | 10,978 | 2,781 |
31 Dec 21 | 43,075 | 7,042 | 11,006 | 2,738 |
30 Sep 21 | 42,308 | 7,208 | 10,593 | 2,623 |
30 Jun 21 | 40,233 | 6,343 | 10,244 | 2,531 |
31 Mar 21 | 37,338 | 5,693 | 9,807 | 2,441 |
31 Dec 20 | 34,608 | 4,449 | 9,591 | 2,420 |
30 Sep 20 | 32,221 | 3,346 | 9,405 | 2,289 |
30 Jun 20 | 31,444 | 3,073 | 9,440 | 2,305 |
31 Mar 20 | 32,095 | 3,539 | 9,597 | 2,318 |
31 Dec 19 | 31,904 | 3,666 | 9,540 | 2,440 |
30 Sep 19 | 31,355 | 3,272 | 9,452 | 2,395 |
30 Jun 19 | 30,935 | 2,867 | 9,403 | 2,373 |
31 Mar 19 | 30,723 | 2,582 | 9,448 | 2,371 |
31 Dec 18 | 30,578 | 2,319 | 9,568 | 2,298 |
30 Sep 18 | 30,402 | 802 | 9,482 | 2,280 |
30 Jun 18 | 29,575 | 812 | 9,141 | 2,274 |
31 Mar 18 | 28,445 | 365 | 8,868 | 2,219 |
31 Dec 17 | 27,390 | 344 | 8,804 | 2,183 |
30 Sep 17 | 25,134 | 1,971 | 8,175 | 1,979 |
30 Jun 17 | 23,607 | 1,055 | 7,808 | 1,763 |
31 Mar 17 | 22,303 | 1,384 | 7,395 | 1,575 |
31 Dec 16 | 20,853 | 1,056 | 6,558 | 1,442 |
30 Sep 16 | 20,708 | 989 | 6,620 | 1,353 |
30 Jun 16 | 20,556 | 1,939 | 6,658 | 1,379 |
31 Mar 16 | 20,393 | 2,124 | 6,648 | 1,392 |
31 Dec 15 | 20,405 | 2,586 | 6,742 | 1,371 |
30 Sep 15 | 20,573 | 2,523 | 6,593 | 1,338 |
30 Jun 15 | 20,502 | 2,365 | 6,522 | 1,265 |
31 Mar 15 | 20,389 | 2,004 | 6,444 | 1,230 |
31 Dec 14 | 20,247 | 1,710 | 6,327 | 1,286 |
30 Sep 14 | 19,905 | 1,560 | 6,373 | 1,343 |
30 Jun 14 | 19,651 | 1,762 | 6,390 | 1,377 |
31 Mar 14 | 19,034 | 1,654 | 6,174 | 1,394 |
31 Dec 13 | 19,657 | 1,970 | 6,340 | 1,371 |
30 Sep 13 | 20,275 | 961 | 6,698 | 1,472 |
30 Jun 13 | 20,715 | 648 | 6,888 | 1,483 |
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (13.9%) are lower than last year (13.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: ABT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABT had negative earnings growth (-3%) over the past year, making it difficult to compare to the Medical Equipment industry average (6.3%).
Return on Equity
High ROE: ABT's Return on Equity (14.5%) is considered low.